Cellerant Therapeutics
San Carlos
About Cellerant Therapeutics
Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. It was founded in 2003 and headquartered in San Carlos, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $109.8M
- Last round: Grant (Sep 2016)
- Website: cellerant.com
- Phone: (650)232-2122
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cellerant-therapeutics-34769 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.